Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial

Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial

“…Disease can recur after surgery, and postprostatectomy radiotherapy can be administered either as adjuvant or as salvage treatment (3)(4)(5)(6). Salvage radiotherapy has been used with success, with factors such as pretreatment prostate-specific antigen (PSA), Gleason score, seminal vesicle invasion, and PSA doubling time determining the rate of success (7).…”

Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node‐positive prostate cancer patients: External validation on a multi‐institutional database

“…However, pN1 PCa patients represent a highly heterogeneous category, sharing not invariably poor oncological outcomes after surgery . In this contest, several long‐term data show excellent cancer control outcomes for patients with favorable pathological features, suggesting that a considerable subset of men with LNM (approximately 30%) remained free of disease, even without any additional treatments . Of note, the state‐of‐the‐art for metastatic PCa patients consists of hormonal therapy, as it leads to prolonged survival up to 85.8% at 10‐year follow up, by turning PCa into a “chronic” disease.…”

Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience

“…To date, about 20% of PCa patients experience PSA persistence after RP [7, 17]. These patients have been found to be at increased risks of disease recurrence and mortality [10, 11].…”

“…Following RP, prostate-specific antigen (PSA) is expected to become undetectable at approximately 6 weeks after surgery. However, up to 20% of patients with adverse pathologic characteristics fail to achieve an undetectable PSA after RP [7-9]. These patients are at a higher risk of recurrence and mortality compared with patients with initially undetectable PSA after surgery [10, 11].…”